Article

Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure

Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305, USA.
Physiological Genomics (Impact Factor: 2.81). 03/2012; 44(10):562-75. DOI: 10.1152/physiolgenomics.00163.2011
Source: PubMed

ABSTRACT MicroRNAs (miRs) are small, noncoding RNAs that are emerging as crucial regulators of cardiac remodeling in left ventricular hypertrophy (LVH) and failure (LVF). However, there are no data on their role in right ventricular hypertrophy (RVH) and failure (RVF). This is a critical question given that the RV is uniquely at risk in patients with congenital right-sided obstructive lesions and in those with systemic RVs. We have developed a murine model of RVH and RVF using pulmonary artery constriction (PAC). miR microarray analysis of RV from PAC vs. control demonstrates altered miR expression with gene targets associated with cardiomyocyte survival and growth during hypertrophy (miR 199a-3p) and reactivation of the fetal gene program during heart failure (miR-208b). The transition from hypertrophy to heart failure is characterized by apoptosis and fibrosis (miRs-34, 21, 1). Most are similar to LVH/LVF. However, there are several key differences between RV and LV: four miRs (34a, 28, 148a, and 93) were upregulated in RVH/RVF that are downregulated or unchanged in LVH/LVF. Furthermore, there is a corresponding downregulation of their putative target genes involving cell survival, proliferation, metabolism, extracellular matrix turnover, and impaired proteosomal function. The current study demonstrates, for the first time, alterations in miRs during the process of RV remodeling and the gene regulatory pathways leading to RVH and RVF. Many of these alterations are similar to those in the afterload-stressed LV. miRs differentially regulated between the RV and LV may contribute to the RVs increased susceptibility to heart failure.

0 Followers
 · 
149 Views
 · 
0 Downloads
  • Source
    • "Mice with severe PS developed edema, decreased RV function, followed by high mortality. In their study, Reddy and colleagues evaluated mice with severe PS at three time points after surgery: early hypertrophy (2 days), late hypertrophy (4 days), and heart failure (10 days) [103]. They demonstrated that the transition from RVH to RVF might be characterized by the expression of miR-34 (upregulated in 10 days PAC only), miR-21 (upregulated in 4 days following PAC and less upregulated in 10 days post-PAC), and miR-1 (downregulated in 4 days PAC and less down in RVF) [98]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance vessel occlusion is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR-206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
    Current Vascular Pharmacology 05/2013; 13(3). DOI:10.2174/15701611113119990010 · 2.91 Impact Factor
  • Source
    • "Mice with severe PS developed edema, decreased RV function, followed by high mortality. In their study, Reddy and colleagues evaluated mice with severe PS at three time points after surgery: early hypertrophy (2 days), late hypertrophy (4 days), and heart failure (10 days) [103]. They demonstrated that the transition from RVH to RVF might be characterized by the expression of miR-34 (upregulated in 10 days PAC only), miR-21 (upregulated in 4 days following PAC and less upregulated in 10 days post-PAC), and miR-1 (downregulated in 4 days PAC and less down in RVF) [98]. "
    Current Vascular Pharmacology 01/2013; · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Profound transcriptional, translational and energetic derangements develop in the right ventricle (RV) in response to physiologic and pathophysiologic stress. The transition from pressure and volume overload to cardiac hypertrophy and subsequent failure is accompanied by a distinct switch from preferential fatty acid to glucose utilization for ATP generation. The failing RV is characterized by an energy-starved state with insufficient ATP levels. Modern non-invasive imaging using positron emission tomography using specific radioactive tracers allows a detailed spatial and temporal characterization of RV metabolism. While the current role for pharmacologic interventions on RV metabolic abnormalities is unclear, several potentially promising molecular targets have been identified and clinical trials targeting molecular dysfunction in RV hypertrophy and failure have been designed.
    Progress in cardiovascular diseases 09/2012; 55(2):229-33. DOI:10.1016/j.pcad.2012.07.010 · 4.25 Impact Factor
Show more